Abbott Laboratories has issued a medical device correction for approximately 3 million FreeStyle Libre 3 and Libre 3 Plus glucose sensors in the U.S. after identifying a production line issue that may result in incorrect low glucose readings. This could lead to incorrect treatment decisions for people with diabetes, posing serious health risks. Globally, Abbott has received reports of 736 severe adverse events and seven deaths potentially linked to this issue, though no deaths have been reported in the U.S. The company has resolved the production issue, continues to supply sensors, and does not anticipate significant supply disruptions. Consumers are advised to check if their sensors are affected at https://www.FreeStyleCheck.com and to discontinue use of impacted sensors immediately. Other Abbott Libre products and devices are not affected.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.
Comments